Form 4: Olema Pharmaceuticals Director Cyrus Harmon Granted Stock Options

Olema Pharmaceuticals, Inc. Director Cyrus Harmon was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months or by the next annual meeting.

Summary

• Cyrus Harmon, a Director of Olema Pharmaceuticals, Inc. (OLMA), was granted 24,150 stock options.
• The stock options have an exercise price of $4.08 per share.
• The options were granted on June 11, 2025, and have an expiration date of June 11, 2035.
• The shares subject to the option vest in 12 successive equal monthly installments starting from June 11, 2025.
• Full vesting will occur on the date of the Issuer's next annual meeting of stockholders if not fully vested by then, subject to continuous service.
• Following this transaction, Cyrus Harmon beneficially owns 24,150 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates standard corporate governance and aligns director interests with shareholders, without any negative surprises.

Positives

• The grant of stock options to Director Cyrus Harmon aligns his financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of executive and director compensation, indicating routine corporate governance practices.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though this is a common aspect of equity compensation plans.

Future Outlook

The stock options are subject to a vesting schedule over 12 successive equal monthly installments from June 11, 2025, or full vesting by the Issuer's next annual meeting of stockholders, contingent on the Reporting Person's continuous service. This indicates an expectation of continued service from the director.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice in the biotechnology and pharmaceutical industry to attract and retain talent and align leadership interests with long-term company performance. Such grants are a standard component of compensation packages for directors and executives in publicly traded companies.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across the biotechnology and pharmaceutical sectors.
• The specific size of the grant (24,150 options) and the exercise price ($4.08) would typically be evaluated against peer companies of similar market capitalization and stage of development, though no specific comparable companies or projects are detailed in this filing.

Corporate Governance

Related Party Transactions

• Grant of 24,150 stock options to Cyrus Harmon, a Director of Olema Pharmaceuticals, Inc., which constitutes a transaction with a related party (insider compensation).

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned director incentives.
• Director (Cyrus Harmon): Receives equity-based compensation, linking personal wealth to company performance.

Next Steps

• The stock options will vest according to the specified schedule (12 monthly installments or by the next annual meeting), contingent on the director's continuous service.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Cyrus Harmon